Tradestie Institutional Equity Comparison Engine

MNOV vs AQST โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MNOV Overall Edge

MNOV Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicinova, Inc. (MNOV) driven by superior Valuation, Momentum & Technical, Options & Structure while AQST counters with relative strength in Growth & Margin. Fundamentally, MNOV trades at 8.5x Forward P/E with -1232.2% operating margin (+12.4% YoY revenue) versus AQST at N/M Forward P/E and -114.1% operating margin (-41.0% YoY). In options structure, MNOV sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro) against AQST sits in BREAKDOWN (64th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MNOV
MNOV 8.5x vs AQST N/M Fwd P/E
Growth & Margin Winner AQST
Op Margin -1232.2% vs -114.1% ยท YoY +12.4% vs -41.0%
Momentum & Technical Winner MNOV
1Y -8.4% vs -40.6% ยท 52W Pos 3% vs 14%
Options & Structure Winner MNOV
UNCLASSIFIED (50th %ile IV) vs BREAKDOWN (64th %ile IV)
MNOV NASDAQ
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
1M Return -7.09%
1Y Return -8.39%
Forward P/E 8.5x
Unified AI Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0
AQST NASDAQ
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.46
-6.61% 1D
Market Cap $465.7M
1M Return -16.22%
1Y Return -40.65%
Forward P/E N/M
Unified AI Score
62.9 / 100 BUY
Tech 54.0 Fund 68.0 Flow 68.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MNOV -8.39% AQST -40.65% Spread: +32.26 pp (MNOV Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MNOV Revenue AQST Revenue MNOV Op. Margin AQST Op. Margin Margin Edge
FY2018 N/A $70M N/A -72.6% AQST
FY2019 N/A $50M N/A -100.1% AQST
FY2020 N/A $50M N/A -93.6% AQST
FY2021 $0M $50M -253.0% -68.2% AQST
FY2022 N/A $50M N/A -88.2% AQST
FY2023 $0M $50M -990.0% -29.9% AQST
FY2024 N/A $60M N/A -53.5% AQST
FY2025 $0M $40M -3242.5% -159.5% AQST

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MNOV (5) vs AQST (5)
Institutional Metric MNOV AQST Criterion Row Winner
Market Capitalization Scale $65.1M $465.7M Larger Scale AQST
Trailing P/E Ratio Valuation 8.5x N/M Lower Multiple MNOV
Forward P/E Ratio Valuation 8.5x N/M Lower Multiple MNOV
Revenue Growth (YoY) Growth +12.4% -41.0% Higher Growth MNOV
Operating Margin (TTM) Profitability -1232.2% -114.1% Higher Margin AQST
Net Profit Margin Profitability 0.0% -162.3% Higher Margin MNOV
Return on Equity (ROE) Capital Efficiency -24.8% 0.0% Higher ROE AQST
52-Week Range Position Momentum 3% ($1โ€“$4) 14% ($3โ€“$7) Stronger Trend AQST
Beta / 30D Volatility Risk Regime 0.59ฮฒ ยท 38% Vol 0.89ฮฒ ยท 56% Vol Lower Realized Risk MNOV
Unified Institutional Score Composite Signal 50.2 / 100 (HOLD) 62.9 / 100 (BUY) Higher Composite AQST

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MNOV vs AQST Buy Guide
MNOV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MNOV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AQST BREAKDOWN
61d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 64th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live AQST Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MNOV nor AQST registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.